Bristol-myers Squibb Compnay

Universitéde Montreal

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Bristol-myers Squibb Holdings Ireland

Daniel H Deon

Edward H Ruediger

Nicholas A Meanwell

Clint A James

Carol Bachand

Alain Martel

Lawrence G Hamann

Andrew Charles Good

Makonen Belema

David R Langley

Lawrence B Snyder

Omar D Lopez

Jeffrey Lee Romine

Denis R St Laurent

Van N Nguyen

Jason T Goodrich

Fukang Yang

Rico Lavoie

Gan Wang

Shoshana L Posy

Marc Gagnon

John F Kadow

R Michael Lawrence

Jacques Banville

Michael Matthew Miller

Pancras C Wong

Julia Guy

Tao Wang

Zhongxing Zhang

Eldon Scott Priestley

Brad D Maxwell

Zhiwei Yin

Roger Remillard

Laurence Dube

Kap-Sun Yeung

David J Carini

Jean-Francois Lavallee

Dietmar A Seiffert

Barry L Johnson

Michael R Lawrence

Roger Rémillard

Francois Tremblay

Zhilei Qiu

François Tremblay

Laurence Dubé

Zhilei Qui

Jean-François Lavallée

Laurence DubÉ

Dietmar Alfred Seiffert

Belema Makonen

The present invention provides thiazole compounds of Formula I wherein W, Y, R, R, R, R, R, R, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation

The present invention provides thiazole compounds of Formula I wherein W, Y, R, R, R, R, R, R, X, X, Xand Xare as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders. 

The present invention provides benzothiazole compounds or benzothiophene compounds of Formula I having the structure: wherein X, X, X, X, X, Y, WR, R, R, R, R, Rand AA and other moieties are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders. 

Benzothiazole and benzothiophene compounds

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, R, R, R, R, X, Xand s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments. 

Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors. 

Tricyclic alkene derivatives as HIV attachment inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors. 

Piperidine amide derivatives as HIV attachment inhibitors

Growing community of inventors

Montreal, Canada

Daniel H Deon